No abstract available.

No abstract available.
Compensation and Redress*

No abstract available.
Encephalitis, Viral*

Polymerase chain reaction (PCR) amplication was used to detect cytomegalovirus (CMV) in tissue culture from the urine of newborns and patients who was suspected CMV infection, Synthetic oligonucleotide primer pairs were used to amplify DNA from the major immediate-early and the phosphoprotein 150 genes of CMV AD 169. Amplified products were detected by gel electrophoresis and by dot-blot hybridization with oligonucleotide probes. We found 12 different tissus culture isolates of CMV after the microimmunoassay using monoclonal antibody to immediate-early antigen. All 12 isolates were positive after PCR amplification. But there was no positive reaction when the same primers and probes were used to amplify herpes simplex virus and human genomic DNA. Twelve urine samples were positive when tested with one or both primer pairs and probes. When compaired tissue culture, detection gel electrophoresis provide a sensitivity of 91% (11/12), dot-blot analysis raised the sensitivity to 100% (12/12). A specificity of both primer was 100%(0/12). We conclude that PCR amplification may be a valuable tool for diagnosing congenital CMV infection.
Cytomegalovirus* ; DNA* ; Electrophoresis ; Humans ; Infant, Newborn ; Oligonucleotide Probes ; Polymerase Chain Reaction* ; Sensitivity and Specificity ; Simplexvirus

No abstract available.
Korea* ; Vaccination*

No abstract available.
Autistic Disorder ; Mercury Poisoning ; Thimerosal*

No abstract available.
Hepatorenal Syndrome*

No abstract available.
Hepatitis B virus* ; Hepatitis B* ; Hepatitis* ; Humans

No abstract available.
Humans ; Infant, Newborn* ; Leukocytes*

BACKGROUND/AIMS: The introduction of Hansenula polymorpha for recombinant hepatitis B vaccine production allowed high product yield with plasmid stability and less glycosylation than conventional Saccharomyces cerevisiae system. A Green Cross HG-II vaccine formulated from HBsAg produced by a recombinant strain of the yeast H. polymorpha was evaluated for immunogenicity and safety in an open label triaL METHOFD: A 20 ug dose of Green Cross HG-II vaccine was administered intramuscularly at 0, 1 and 6 months at the deltoid region in 118 healthy adults seronegative for HBV markers. The anti-HBs titers were determined at one month after administration of the third dose of vaccine by radioimmunoassay. RESULTS: The seroconversion rate was 96.8% (90 out of 93), with seroprotective rate of 95.7% (89 out of 93). The geometric mean titers(GMT) of the anti-HBs response was 153.1mIU/ml in seroconverters. An age-dependent effect was observed in the anti-HBs response. But sex-dependent effect was not prominent. Reactogenecity was in incidence and general reactions were short-lasting and a mainly mild in severity. CONCLUSIONS: The results of this study have shown that the Green Cross HG-II vaccine is safe and clinically well tolerated, a nd that it may provide protection against HBV infection.
Adult* ; Glycosylation ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines* ; Hepatitis B* ; Hepatitis* ; Humans ; Incidence ; Pichia ; Plasmids ; Radioimmunoassay ; Saccharomyces cerevisiae ; Yeasts